Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paroxetine Mesylate

FDA-approved product (tablet, oral), marketed as Paroxetine, Paroxetine Hydrochloride, Paxil and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Paroxetine Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety disorder
  • Depressive disorder
  • Major depressive disorder
  • Menopause
  • Obsessive-compulsive disorder
  • Panic disorder
  • Post-traumatic stress disorder
  • Social anxiety disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective serotonin reuptake inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli23.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae19.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Paroxetine Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paroxetine Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER

    NCT00791713 · start 2006-03

    Registered record
    Registry ID
    NCT00791713
    Conditions
    Schizophrenia
    Interventions
    Paliperidone ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-03
    Completion
    2006-07
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPaliperidone ER
    PhasePhase 1
    Registry statusCompleted

  • Clinical Pharmacogenomics of Antidepressant Response

    NCT00384020 · start 2006-01

    Registered record
    Registry ID
    NCT00384020
    Conditions
    Depression
    Interventions
    Paroxetine (Seroxat); Escitalopram (Lexapro)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-01
    Completion
    2010-01
    Enrolment
    402

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionParoxetine (Seroxat); Escitalopram (Lexapro)
    PhaseNot recorded
    Registry statusCompleted

  • Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)

    NCT00560612 · start 2006-01

    Registered record
    Registry ID
    NCT00560612
    Conditions
    Stress Disorders, Post-Traumatic
    Interventions
    Paroxetine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-01
    Completion
    2008-07
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStress Disorders, Post-Traumatic
    InterventionParoxetine; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Seroquel in Bipolar Depression Versus SSRI

    NCT00119652 · start 2005-05

    Registered record
    Registry ID
    NCT00119652
    Conditions
    Bipolar Disorder; Bipolar Depression; Depression
    Interventions
    quetiapine fumarate (Seroquel); paroxetine; mood stabilizing activity
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-05
    Completion
    2007-05
    Enrolment
    676

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder; Bipolar Depression; Depression
    Interventionquetiapine fumarate (Seroquel); paroxetine; mood stabilizing activity
    PhasePhase 3
    Registry statusCompleted

  • PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients

    NCT00343707 · start 2004-11

    Registered record
    Registry ID
    NCT00343707
    Conditions
    Depressive Disorder and Anxiety Disorders
    Interventions
    vestipitant; paroxetine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-11
    Completion
    2005-11
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder and Anxiety Disorders
    Interventionvestipitant; paroxetine
    PhasePhase 2
    Registry statusCompleted

  • Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance

    NCT00202449 · start 2004-07

    Registered record
    Registry ID
    NCT00202449
    Conditions
    Stress Disorders, Post-Traumatic; Sleep Disorders
    Interventions
    prazosin; paroxetine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2004-07
    Completion
    2008-02
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStress Disorders, Post-Traumatic; Sleep Disorders
    Interventionprazosin; paroxetine; Placebo
    PhaseNot applicable
    Registry statusTerminated

  • Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder

    NCT00113295 · start 2004-02

    Registered record
    Registry ID
    NCT00113295
    Conditions
    Anxiety Disorder
    Interventions
    Continued Paroxetine CR; Quetiapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-02
    Completion
    2007-11
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety Disorder
    InterventionContinued Paroxetine CR; Quetiapine; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder

    NCT00074802 · start 2003-12

    Registered record
    Registry ID
    NCT00074802
    Conditions
    Social Anxiety Disorder
    Interventions
    Paroxetine; Cognitive behavioral therapy (CBT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-12
    Completion
    2008-05
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSocial Anxiety Disorder
    InterventionParoxetine; Cognitive behavioral therapy (CBT)
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine

    NCT00825019 · start 2003-09

    Registered record
    Registry ID
    NCT00825019
    Conditions
    Major Depressive Disorders
    Interventions
    amibegron (SR58611A); placebo; paroxetine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-09
    Completion
    2004-12
    Enrolment
    306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorders
    Interventionamibegron (SR58611A); placebo; paroxetine
    PhasePhase 3
    Registry statusCompleted

  • Treatment of Depression in Parkinson's Disease Trial

    NCT00062738 · start 2003-06

    Registered record
    Registry ID
    NCT00062738
    Conditions
    Parkinson Disease; Depression
    Interventions
    paroxetine; Nortriptyline; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-06
    Completion
    2009-01
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease; Depression
    Interventionparoxetine; Nortriptyline; placebo
    PhasePhase 2
    Registry statusCompleted

  • Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients

    NCT00817375 · start 2003-02

    Registered record
    Registry ID
    NCT00817375
    Conditions
    Depression; Adverse Reaction to Drug
    Interventions
    SSRI treated group; non-SSRI treated group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2003-02
    Completion
    2018-12
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Adverse Reaction to Drug
    InterventionSSRI treated group; non-SSRI treated group
    PhaseNot applicable
    Registry statusUnknown

  • Predict Antidepressant Responsiveness Using Pharmacogenomics

    NCT01228357 · start 2003-02

    Registered record
    Registry ID
    NCT01228357
    Conditions
    Depression; Depressive Symptoms
    Interventions
    SSRI treated group; non-SSRI treated group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2003-02
    Completion
    2018-12
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Depressive Symptoms
    InterventionSSRI treated group; non-SSRI treated group
    PhaseNot applicable
    Registry statusUnknown

  • Study Evaluating Venlafaxine ER in Patients With Panic Disorder

    NCT00044772 · start 2001-11

    Registered record
    Registry ID
    NCT00044772
    Conditions
    Panic Disorder
    Interventions
    Venlafaxine ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-11
    Completion
    2003-04
    Enrolment
    653

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPanic Disorder
    InterventionVenlafaxine ER
    PhasePhase 3
    Registry statusCompleted

  • Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)

    NCT00034983 · start 2001-10-29

    Registered record
    Registry ID
    NCT00034983
    Conditions
    Major Depressive Disorder
    Interventions
    aprepitant; Comparator: paroxetine HCL
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-10-29
    Completion
    2003-12-29
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    Interventionaprepitant; Comparator: paroxetine HCL
    PhasePhase 3
    Registry statusCompleted

  • Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

    NCT00035009 · start 2001-09-20

    Registered record
    Registry ID
    NCT00035009
    Conditions
    Major Depressive Disorder
    Interventions
    MK0869, aprepitant; Comparator: paroxetine HCL
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-09-20
    Completion
    2004-03-24
    Enrolment
    468

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionMK0869, aprepitant; Comparator: paroxetine HCL
    PhasePhase 3
    Registry statusCompleted